Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu - LARVOL DELTA

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - P1 | N=154 | Terminated | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Oct 2026 ➔ May 2026 | Active, not recruiting ➔ Terminated | Trial primary completion date: Oct 2026 ➔ May 2026; < 75 % participation

Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • Endocrine Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Genetic Disorders • Gynecologic Cancers • Head and Neck Cancer • Neurofibromatosis • Oncology • Oral Cancer • Pulmonary Disease • Rare Diseases • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thoracic Cancer • Thyroid Gland Carcinoma • Urothelial Cancer

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - P1 | N=155 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Mar 2026 ➔ Oct 2026 | Trial primary completion date: Mar 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • Breast Cancer • Endocrine Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Genetic Disorders • Gynecologic Cancers • Head and Neck Cancer • Neurofibromatosis • Oncology • Oral Cancer • Pulmonary Disease • Rare Diseases • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thoracic Cancer • Thyroid Gland Carcinoma • Urothelial Cancer

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - P2 | N=210 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Choroidal Melanomas • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - P1 | N=155 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Mar 2024 ➔ Mar 2026 | Trial primary completion date: Mar 2024 ➔ Mar 2026

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Endocrine Cancer • Fibrosis • Gastrointestinal Cancer • Gastrointestinal Disorder • Genetic Disorders • Gynecologic Cancers • Head and Neck Cancer • Neurofibromatosis • Oncology • Oral Cancer • Pulmonary Disease • Rare Diseases • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thoracic Cancer • Thyroid Gland Carcinoma • Urothelial Cancer

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - P2 | N=210 | Active, not recruiting | Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Trial completion date • Trial primary completion date • Choroidal Melanomas • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - P2 | N=210 | Active, not recruiting | Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Choroidal Melanomas • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - P1 | N=155 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Mar 2023 ➔ Mar 2024 | Trial primary completion date: Mar 2023 ➔ Mar 2024

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Endocrine Cancer • Fibrosis • Gastrointestinal Cancer • Gastrointestinal Disorder • Genetic Disorders • Gynecologic Cancers • Head and Neck Cancer • Neurofibromatosis • Oncology • Oral Cancer • Pulmonary Disease • Rare Diseases • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thoracic Cancer • Thyroid Gland Carcinoma • Urothelial Cancer

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - P2 | N=210 | Active, not recruiting | Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University | N=150 ➔ 210 | Trial primary completion date: Dec 2022 ➔ Jun 2023

Enrollment change • Trial primary completion date • Choroidal Melanomas • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma (clinicaltrials.gov) - P2 | N=150 | Active, not recruiting | Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2022 ➔ Jun 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Enrollment closed • Trial completion date • Trial primary completion date • Choroidal Melanomas • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - P1 | N=155 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Mar 2022 ➔ Mar 2023 | Trial primary completion date: Mar 2022 ➔ Mar 2023

Combination therapy • Trial completion date • Trial primary completion date • Breast Cancer • Endocrine Cancer • Fibrosis • Gastrointestinal Cancer • Gastrointestinal Disorder • Genetic Disorders • Gynecologic Cancers • Head and Neck Cancer • Neurofibromatosis • Oncology • Oral Cancer • Pulmonary Disease • Rare Diseases • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thoracic Cancer • Thyroid Gland Carcinoma • Urothelial Cancer

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - P1; N=155; Active, not recruiting; Sponsor: M.D. Anderson Cancer Center; Recruiting ➔ Active, not recruiting; Trial completion date: Mar 2021 ➔ Mar 2022; Trial primary completion date: Mar 2020 ➔ Mar 2022

Clinical • Combination therapy • Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • Endocrine Cancer • Fibrosis • Gastrointestinal Cancer • Genetic Disorders • Gynecologic Cancers • Head and Neck Cancer • Neurofibromatosis • Oncology • Oral Cancer • Pulmonary Disease • Rare Diseases • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thoracic Cancer • Thyroid Gland Carcinoma • Urothelial Cancer

Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma (clinicaltrials.gov) - P2; N=150; Recruiting; Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University; Trial completion date: Dec 2021 ➔ Jul 2022; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Choroidal Melanomas • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer (clinicaltrials.gov) - P1; N=50; Completed; Sponsor: Barbara Ann Karmanos Cancer Institute; Recruiting ➔ Completed; N=180 ➔ 50; Trial completion date: Dec 2017 ➔ Nov 2018; Trial primary completion date: Dec 2017 ➔ Sep 2018

Biomarker • Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date